ArticleCellular & molecular biology letters2026
Toll-like receptor 2 drives liver senescence and fibrosis in aging through gut-derived microbial signaling.
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toll-like receptor 2 modulates age-associated insulitis and fibrotic remodeling of Langerhans islets.Immunity & ageing : I & A · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile the role of endotoxins from Gram-negative bacteria has been studied extensively, the contribution of Gram-positive bacterial components—particularly those activating toll-like receptor 2 (TLR2), such as lipoteichoic acid (LTA)—to liver aging, inflammation, and fibrosis remains poorly understood. Here, we investigated the role of TLR2 and its ligand LTA in liver aging by using murine models, in vitro experiments, and human samples from young and elderly individuals.
methodsTLR2 ligands were evaluated in serum samples from young (aged 21–33 years) and elderly (aged 65–77 years) healthy individuals. Markers of liver damage, senescence, and inflammation were assessed in 4- and 20-month-old male C57BL/6 and TLR2 knockout (TLR2−/−) mice. In addition, 17-month-old male C57BL/6 mice were treated either with the TLR2 inhibitor ortho-vanillin (60 mg/kg BW in drinking water) or plain water for 4 months and markers as determined above were assessed. The presence of markers of senescence was measured in J774A.1 cells and human peripheral blood mononuclear cells stimulated with LTA.
resultsIn humans and mice, aging was associated with significantly elevated circulating levels of TLR2 ligands. In aging mice, this was accompanied by increased hepatic Tlr2 mRNA expression. Strikingly, 20-month-old male TLR2−/− mice exhibited reduced markers of senescence (e.g., plasma plasminogen activator inhibitor-1 and liver p16 expression), inflammation (e.g., hepatic neutrophil infiltration, Il1b mRNA expression), and fibrosis (e.g., α-smooth muscle actin expression, Sirius Red staining), compared with age-matched wild-type controls. Similarly, in aged male C57BL/6 J mice showing first signs of impaired intestinal barrier function i.e., rising peripheral TLR2 ligand levels in plasma, treatment with the TLR2 inhibitor ortho-vanillin for 4 months attenuated the progression of liver aging as indicated by attenuated senescence, liver inflammation, and fibrosis. In vitro, stimulation of J774A.1 macrophages and human peripheral blood mononuclear cells with LTA induced the expression of senescence-associated genes p16 and p21.
conclusionsCollectively, these findings suggest that increased translocation of TLR2 ligands and subsequent activation of TLR2-dependent pathways play a critical role in age-associated liver degeneration. Targeting TLR2 signaling may therefore represent a promising therapeutic approach to mitigate hepatic aging and associated pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.